Biohaven Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neurological and neurodegenerative diseases. Established in 2013 and headquartered in New Haven, Connecticut, Biohaven leverages its proprietary portfolio of small molecule and peptide-based drug candidates to address areas of high unmet medical need. The company’s research and development efforts span a variety of neurological conditions, including migraine, rare genetic disorders, and other central nervous system (CNS) diseases.
Biohaven’s lead commercial product is rimegepant, marketed under the brand name Nurtec® ODT, an orally disintegrating tablet approved for the acute treatment of migraine and preventive therapy. In addition to rimegepant, the company is advancing zavegepant, an intranasal calcitonin gene-related peptide (CGRP) receptor antagonist, through regulatory review in multiple regions. Beyond its migraine franchise, Biohaven’s pipeline encompasses novel candidates targeting neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as strategic collaborations to enhance development and commercial reach.
Throughout its history, Biohaven has engaged in key partnerships and licensing agreements to expand its global footprint. After an initial collaboration with Pfizer for the development and commercialization of rimegepant, Biohaven reacquired full worldwide rights to the asset, enabling direct control over its strategic positioning. The company maintains a presence in major markets across North America, Europe, and Asia, and continues to explore new alliances to support late-stage clinical programs and future launches.
Led by Founder and CEO Vlad Coric, M.D., Biohaven’s leadership team comprises seasoned executives with extensive experience in neuroscience, regulatory affairs, and global commercialization. The board and management emphasize a patient-centric approach and aim to bring transformative therapies to those affected by debilitating CNS disorders. With a strategy grounded in innovative science and disciplined execution, Biohaven is positioned to address significant unmet needs in neurology while building a sustainable franchise for long-term growth.
AI Generated. May Contain Errors.